Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: A single-institution cohort

Desai, Mihir J.; Liu, Shilin; Parker, Sareeta

doi:10.1016/j.jaad.2014.10.019

Cited by 59 publications

(65 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For response in advanced stage disease, clinical data on nodal and visceral response were accounted for, in line with guidelines . Disease progression was defined as progression to a more advanced TNMB stage (excluding a change from T1a/T2a to T1b/T2b, respectively) or death related to MF/SS …”

Section: Methodssupporting

confidence: 84%

Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi‐ethnic Asian cohort: a 12‐year review

Lim

Tan

Tee

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Limited information exists regarding survival of Asian patients with mycosis fungoides (MF) and Sézary syndrome (SS). Objective To evaluate the epidemiology, outcome and prognostic factors of these patients. Methods A retrospective review of MF/SS cases diagnosed from 2000 to 2011 at a tertiary referral dermatology centre in Singapore was performed. Results Of 246 patients, 63% were male and the median age at diagnosis was 49 years. 73.2% were Chinese, 12.6% Indian, 6.9% Malay and 7.3% Caucasian. A total of 239 patients (97.2%) had MF and seven had SS. Median follow‐up duration was 6.3 years, and median duration of symptoms at diagnosis was 13 months. For patients with MF, the majority had early disease (92.8% stage IA–IIA). 3.8% were stage IIB, 1.7% stage III and 1.7% stage IV. Complete response to treatment occurred in 78.2%, partial response in 9.6%, persistent but non‐progressive disease in 10.0% and disease progression in 4.1% of patients. Large cell transformation occurred in 4.1% of patients. Mean overall survival during this study was 12.7 years, with death occurring in 2.5% of patients (all ≥stage IIB at diagnosis). For patients with SS, 71.4% presented with stage IVA disease, 28.6% stage IVB. Complete response to treatment occurred in 14.2%, persistent but non‐progressive disease in 28.6% and disease progression in 57.2% of patients. Mean overall survival was 3.3 years within this study, with death occurring in 42.9% of SS patients. Prognostic factors associated with favourable recurrence‐free survival were male gender (P = 0.008), early disease stage (T1) at diagnosis (P < 0.001) and absence of maintenance treatment after remission (P = 0.01). Conclusion Compared to Caucasian and East Asian cohorts, MF in South‐East Asians was diagnosed at a younger age and associated with lower mortality, largely due to greater prevalence of hypopigmented MF.

show abstract

Section: Methodssupporting

confidence: 84%

Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi‐ethnic Asian cohort: a 12‐year review

Lim

Tan

Tee

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…MF has a wide range of clinical presentations and rarely has been reported to involve the nail apparatus [1]. The clinical presentations of nail involvement in previous case reports included subungual hyperkeratosis, onycholysis, onychomadesis, yellow discoloration, thinning of the nail plate, splinter hemorrhage, and 20-nail dystrophy [2,3,4,5,6,7,8,9,10].…”

Section: Discussionmentioning

confidence: 99%

“…Mycosis fungoides (MF) accounts for nearly 50% of all cases. The classic type of MF is characterized by infiltration of atypical T lymphocytes with cerebriform nuclei in the papillary dermis and evidence of epidermotropism (i.e., presence of atypical T-cell lymphocytes in the epidermis without significant spongiosis) [1]. Classic MF typically exhibits slow progression in the first years after diagnosis and rarely progresses to extracutaneous involvement or disease-related death.…”

Section: Introductionmentioning

confidence: 99%

Nail Changes in Early Mycosis Fungoides

Ehsani

Nasimi

Azizpour

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

Background: Mycosis fungoides (MF) has a wide range of clinical presentations and it has been reported rarely to involve the nail apparatus. Objective: We intended to evaluate the frequency and characteristics of nail changes in patients with biopsy-proven MF. Methods: A retrospective analysis of 60 patients with MF who were evaluated at our cancer center from 2013 to 2014 was performed to identify patients with nail changes. Histological examinations of the skin around the nail apparatus were obtained from 10 patients with periungual skin erythema and scaling. Results: In 45 patients out of 60 cases, the skin around the nail apparatus was normal, and only in 5 patients of these 45 cases, nail changes were detected. These changes included leukonychia, longitudinal ridging, nail thickening, and opacity. In the remaining 15 patients, erythema and scaling was observed in periungual skin, and 13 of them demonstrated nail changes including longitudinal ridging, nail thickening, fragility of the nail plate, subungual hyperkeratosis, pigmented nail band, Beau's lines, onychomadesis, koilonychia, nail thinning, distal notching, subungual debris, leukonychia, and pitting. In biopsies of periungual skin, none of 10 cases revealed histological findings consistent with MF. Conclusions: Evidence of nail changes was observed in 18 cases (30%). The most common nail changes detected in MF patients included longitudinal ridging, nail thickening, nail fragility, and leukonychia.

show abstract

“…MF is the only primary cutaneous lymphoma with no primary lymph node malignancy counterpart. Indolent neoplasm with insidious progression can suffer a transformation to an aggressive large-cell lymphoma 1,20 . It is composed of different clinical variants and characterized by marked epidermotropism 21 .…”

Section: Cutaneous T-cell Lymphomas (Ctcl)mentioning

confidence: 99%

“…Eventually, MF undergoes a transformation to a large-cell lymphoma, with tumorous lesions that are unresponsive to treatment and more likely to spread and involve lymph nodes 22 . 20 . Treatment depends on the stage and clinical presentation of the disease.…”

Section: Classical Mfmentioning

confidence: 99%

Cutaneous lymphomas: A review

Miyashiro¹,

Sanches²

2015

Cumhuriyet Med J

View full text Add to dashboard Cite

SUMMARYSkin may be affected by non-Hodgkin lymphomas, and it is the second most frequently involved extranodal organ, after the gastrointestinal tract. Cutaneous lymphomas may originate from T, B, or NK lymphocytes. Diagnosis is difficult, and knowledge of these diseases is important to ensure their detection and adequate treatment and follow-up. Clinical picture is heterogeneous, and histology is essential to confirm the diagnosis. The classification is given by the correlation between clinical findings, histology and immunophenotyping. Therapeutic options include skin-directed therapies, immunomodulatory or low-dose immunosuppressive drugs. Rare cases of aggressive disease require systemic multidrug chemotherapy. The purpose of this review is to describe the ontogeny of T, B and NK lymphocytes, and to detail the most accepted classification of cutaneous lymphomas, proposed by the World Health Organisation and European Organisation for Research and Treatment of Cancer. Treatment of cutaneous lymphomas will be briefly discussed.

show abstract

Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: A single-institution cohort

Cited by 59 publications

References 31 publications

Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi‐ethnic Asian cohort: a 12‐year review

Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi‐ethnic Asian cohort: a 12‐year review

Nail Changes in Early Mycosis Fungoides

Cutaneous lymphomas: A review

Contact Info

Product

Resources

About